Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR2 | Q13873 | 2/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 6/20 | 0.32 |
| ▸ | JAK1 | P23458 | 6/20 | 0.32 |
| ▸ | TYK2 | P29597 | 6/20 | 0.32 |
| ▸ | JAK3 | P52333 | 6/20 | 0.32 |
| ▸ | FLT3 | P36888 | 3/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | STK4 | Q13043 | 1/20 | 0.31 |
| ▸ | STK3 | Q13188 | 1/20 | 0.31 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.31 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 2/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL416072 | 0.93 | BMPR2 (0.38) | BMPR2GSK3AGSK3BJAK2JAK1 | |
| SCHEMBL413916 | 0.90 | CHEK1 (0.40) | BMPR2GSK3AGSK3BLMNAPKM | |
| SCHEMBL415046 | 0.88 | BMPR2 (0.37) | BMPR2GSK3AGSK3BJAK2JAK1 | |
| SCHEMBL10290242 | 0.87 | GSK3A (0.34) | BMPR2GSK3AGSK3BJAK2JAK1 | |
| SCHEMBL414534 | 0.87 | GSK3A (0.37) | BMPR2GSK3AGSK3BJAK2JAK1 | |
| SCHEMBL415050 | 0.86 | GSK3A (0.36) | BMPR2GSK3AGSK3BJAK2JAK1 | |
| SCHEMBL10291311 | 0.84 | BMPR2 (0.39) | BMPR2GSK3AGSK3BJAK2JAK1 | |
| SCHEMBL416074 | 0.81 | BMPR2 (0.40) | BMPR2GSK3AGSK3BJAK2JAK1 | |
| SCHEMBL415990 | 0.81 | BMPR2 (0.40) | BMPR2GSK3AGSK3BJAK2JAK1 | |
| SCHEMBL415076 | 0.81 | CHEK1 (0.39) | BMPR2GSK3AGSK3BCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394955-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8148388-B2 | 2,4 (4,6) pyrimidine derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2012-03-15 | — | — | US | disclosed |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065395-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR0B1, NR1H3, NCOA3 | BMPR2 1442/4885GSK3A 4077/4885GSK3B 4007/4885 |
| US-20100160310-A1 | 2,4 (4,6) PYRIMIDINE DERIVATIVES | NR1H3, NR1H2, NR0B1 | BMPR2 1474/4885GSK3A 3787/4885GSK3B 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.